Date: 2013-01-07
Type of information: R&D agreement
Compound: RNA-based therapeutics
Company: Ethris (Germany) Shire (UK)
Therapeutic area: Genetic diseases - Rare diseases
Type agreement: R&D
Action mechanism:
Disease: monogenic genetic diseases
Details: Ethris GmbH and Shire have initiated a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. Ethris and its co-founders – Dr. Carsten Rudolph and Prof. Christian Plank, have developed a novel RNA modification technology that creates Stable and Non-Immunogenic Messenger RNA (SNIM®-RNA) molecules that are suited for use in protein replacement therapies to treat monogenic genetic diseases. Under this partnership, the two companies aims to develop an RNA modification and delivery technology that efficiently results in protein replacement in relevant cellular populations.
Financial terms: Financial details were not disclosed.
Latest news:
